The end synthesized chemical structure of Pt-Mal-LHRH resembles the less toxic carboplatin while also using LHRH to tailor in-vivo distribution more selectively to the tumor tissues while decreasing excess systemic distribution. Here, GNRH1 is linked to neoplasm.